Clinical Core

临床核心

• 批准号: 10407979
• 负责人: DOUGLAS R GALASKO
• 金额: $ 114.83万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10407979
• 关键词: Address; Adopted; Age; Aging; Alzheimer' s Disease; Area; Autopsy; Biochemical; Biological Markers; Biopsy; Blood; Blood specimen; Brain; Brain Chemistry; Brain Pathology; Brain imaging; Cells; Cessation of life; Classification; Clinical; Clinical Research; Clinical Trials; Cognition; Cognitive; Cognitive aging; Consent; DNA; Data; Data Set; Data Store; Databases; Dementia; Diagnosis; Disease; Early Diagnosis; Elderly; Enrollment; Environment; Excision; Funding; Genetic; Heterogeneity; Hippocampus (Brain); Human Microbiome; Image; Latino; Latino Population; Lewy Body Disease; Link; Magnetic Resonance Imaging; Measures; Medical Genetics; Memory; Methodology; Mexican Americans; Neurodegenerative Disorders; Participant; Pathology; Persons; Phenotype; Physiological; Plasma; Pluripotent Stem Cells; Population; Positron-Emission Tomography; Quality Control; Registries; Research; Research Support; Sampling; Skin; Spinal Puncture; Staging; Structure; Symptoms; Temporal Lobe; Testing; United States National Institutes of Health; Variant; Work; aging brain; alpha synuclein; biomarker evaluation; brain magnetic resonance imaging; cell transformation; clinical phenotype; clinically significant; cognitive testing; cohort; data management; data sharing; dementia risk; follow-up; hazard; hippocampal sclerosis; imaging genetics; indexing; induced pluripotent stem cell; innovation; interest; meetings; member; metabolomics; mild cognitive impairment; minority subjects; neuropathology; novel; novel marker; outreach; pre-clinical; ranpirnase; recruit; response; social; symposium; tau Proteins; volunteer

CLINICAL CORE SUMMARY/ ABSTRACT The primary aim of the Clinical Core will be to enroll, characterize and follow a cohort maintained at 500-600 elders to support many types of research into Alzheimer’s Disease and Related Disorders. People who are enrolled will include some with normal cognition, some of whom may have markers of Alzheimer’s in their brain already, people with mild cognitive impairment and mild Alzheimer’s, and people with other types of neurodegenerative disorders, including Lewy Body Disease and Fronto-Temporal Lobar Degeneration. The core will enroll minority subjects as part of the groups that are followed, in particular Latinos. In addition to collecting and storing data about the ADRC participants at UCSD, the core will include components that are part of a national effort across centers, called the Uniform Data Set (UDS). The Core will submit UDS data on all subjects it follows to the national Alzheimer’s Coordinating Center (NACC). This will allow data sharing with a large national database. The Clinical Core will perform further testing beyond the tests required for the UDS. The core will draw a sample of blood for DNA, plasma and serum from participants, and will obtain CSF samples by lumbar puncture from those who agree. The core will obtain skin biopsies to be used to transform the cells in the skin into cells that can change into many identities (called pluripotent stem cells). Participants will have MRI brain imaging and PET imaging to support research into brain changes and pathology. Blood, CSF, skin biopsies and imaging will be stored at UCSD to allow for further analysis, and it may be available to share with collaborators. All participants will be invited to undergo follow-up research assessments once per year, to determine change in brain functioning, memory and other abilities. In subjects who consent, after their death the core will arrange for autopsy removal of the brain, for pathology analysis and to support further research. Some of the particular areas where the core will focus its efforts are in novel cognitive tests and assessing the brain through biomarkers related to structure, function, pathology and chemistry of the brain. This may help in early detection of change before major symptoms of dementia have arisen. Alzheimer’s disease has different features and progresses at varying rates, and we will try to identify factors that may account for this variation. Another area of interest for the core is in developing better ways to assess Latino participants, supported through social, cultural, and research expertise of the Latino Core. Finally, the core will work with other members of the ADRC to maintain and expand a Registry of research- ready volunteers.

临床核心摘要/摘要 临床核心的主要目标将是登记、描述和遵循保持在500-600的队列 支持多种类型的阿尔茨海默氏症及相关疾病的研究。人们是谁 参加注册的人包括一些认知正常的人，其中一些人的大脑中可能有阿尔茨海默氏症的标志 已经，患有轻度认知障碍和轻度阿尔茨海默氏症的人，以及其他类型的 神经退行性疾病，包括路易体病和额颞叶变性。这个 CORE将招募少数族裔受试者作为后续群体的一部分，特别是拉丁裔。 除了收集和存储加州大学圣迭戈分校ADRC参与者的数据外，核心将包括 这些组件是国家跨中心工作的一部分，称为统一数据集(UDS)。核心意志 将其跟踪的所有受试者的UDS数据提交给国家阿尔茨海默氏症协调中心(NACC)。这将是 允许与大型国家数据库共享数据。临床核心将进行进一步的测试，超出 UDS所需的测试。 中心将从参与者那里提取血液DNA、血浆和血清样本，并将获得脑脊液。 同意的人通过腰椎穿刺法采集样本。核心将获得皮肤活组织检查，用于转化 皮肤中的细胞可以转变为多种身份的细胞(称为多能干细胞)。参与者 将进行核磁共振脑成像和PET成像，以支持对大脑变化和病理的研究。鲜血， 脑脊液、皮肤活检和成像将存储在加州大学圣迭戈分校，以便进行进一步分析，并可能用于 与合作者分享。 所有参与者将被邀请接受每年一次的后续研究评估，以确定 大脑功能、记忆和其他能力的变化。在同意的受试者中，他们死后核心将 安排尸检取出大脑，进行病理分析，并支持进一步的研究。 核心将重点关注的一些特定领域是新颖的认知测试和评估 通过与大脑的结构、功能、病理和化学相关的生物标志物。这可能有助于 在痴呆症的主要症状出现之前，及早发现变化。阿尔茨海默病有不同的 特征和进展速度各不相同，我们将努力确定可能导致这种差异的因素。 核心的另一个感兴趣的领域是开发更好的方法来评估拉丁裔参与者，支持 通过拉丁裔核心的社会、文化和研究专业知识。 最后，该核心将与ADRC的其他成员合作，维护和扩大研究登记处- 准备好的志愿者。